Published on February 25, 2020 Background This phase Ib/II study was designed to evaluate the safety and efficacy of a novel immunotherapy and VEGF-directed therapy combination as first line treatment…
Published on February 26, 2020 Background In heavily pretreated patients, for whom there remains a tremendous unmet need with limited options beyond single-agent chemotherapy, which generates responses in just 12%…
Background While standard protocols such as chemotherapy are still widely used, clinical trials are supporting the discovery of new treatments and some have proven to be very effective. CAR-T cell…
Published on February 15, 2020 Background Scientists report promising activity of the novel an oral first-in-class MK-6482 drug that targets a key driver of clear cell Renal Cell Carcinoma (ccRCC)…
Background In the phase III trial, more than 300 patients with metastatic RCC were randomly chosen to receive Fotivda (Tivozanib) or Nexavar (Sorafenib) for a median of 19 months. While…
The triplet of Opdivo, Cyramza and Paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer. The impact of PD-L1 expression…
Published February 5, 2020 Background Capivasertib (AZD5363) is an oral inhibitor of AKT and by that it influences cell division, apoptosis and cell metabolism. The FAKTION study investigated whether the…
Published on January 21, 2020 Background In this trial, 137 cancer patients with NO AVAILABLE STANDARD THERAPEUTIC OPTIONS were treated with the combination of Lenvima plus Keytruda. Eligible patients had…
Background - A woman in her sixties was diagnosed about two years ago with Small Cell Lung Cancer, SCLC (15% of all lung cancer patients are diagnosed with this type…
Background - 6 months ago, M.N., 38, was diagnosed with an extremely rare and aggressive type of cancer. A cancer that progresses tremendously rapidly in the body, very deadly. Out…